Erectile dysfunction may improve by blood pressure control in patients with high-risk hypertension

Postgraduate Medicine

Volumn 122, Issue 6, 2010, Pages 51-56

  Cordero, Alberto ^a   Bertomeu Martínez, Vicente ^a   Mazón, Pilar ^b   Fácila, Lorenzo ^c   González Juanatey, José Ramón ^b  

^a HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c Hospital Provincial de Castellon   (Spain)

Author keywords

Age; Blood pressure control; Comorbidities; Erectile dysfunction; High risk hypertension

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOPROLOL; NEBIVOLOL; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; AGE DISTRIBUTION; AGED; AGING; ARTICLE; BLOOD PRESSURE REGULATION; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; ERECTILE DYSFUNCTION; HIGH RISK HYPERTENSION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; CONFIDENCE INTERVAL; FOLLOW UP; HOSPITALIZATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK; RISK ASSESSMENT; STATISTICAL MODEL; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGE DISTRIBUTION; AGED; ANTIHYPERTENSIVE AGENTS; CHI-SQUARE DISTRIBUTION; CONFIDENCE INTERVALS; CROSS-SECTIONAL STUDIES; ERECTILE DYSFUNCTION; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PREVALENCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79952197938     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.11.2223     Document Type: Article

References (37)

1. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA. 1993;270(1):83-90.
2. Lue TF. Erectile dysfunction. N Engl J Med. 2000;342(24):1802-1813.
3. Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med. 2007;120(2):151-157.
4. Chew KK, Earle CM, Stuckey BG, Jamrozik K, Keogh EJ. Erectile dysfunction in general medicine practice: prevalence and clinical correlates. Int J Impot Res. 2000;12(1):41-45.
5. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151(1):54-61.
6. Maroto-Montero JM, Portuondo-Maseda MT, Lozano-Suárez M, et al. Erectile dysfunction in patients in a cardiac rehabilitation program. Rev Esp Cardiol. 2008;61(9):917-922.
7. Inman BA, Sauver JL, Jacobson DJ, et al. A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc. 2009;84(2):108-113.
8. Nehra A. Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions. Mayo Clin Proc. 2009;84(2):139-148.
9. Kushiro T, Takahashi A, Saito F, et al. Erectile dysfunction and its influence on quality of life in patients with essential hypertension. Am J Hypertens. 2005;18(3):427-430.
10. Miner MM. Erectile dysfunction and the "window of curability": a harbinger of cardiovascular events. Mayo Clin Proc. 2009;84(2):102-104.
11. Cordero A, Bertomeu-Martínez V, Mazon P, et al. Erectile dysfunction in high-risk hypertensive patients treated with beta-blockade agents. Cardiovasc Ther. 2010;28(1):15-22.
12. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303(20):2043-2050.
13. O'Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376(9735):112-123.
14. Chamnan P, Simmons RK, Khaw KT, Wareham NJ, Griffin SJ. Estimating the population impact of screening strategies for identifying and treating people at high risk of cardiovascular disease: modelling study. BMJ. 2010;340:c1693.
15. Wijeysundera HC, Machado M, Farahati F, et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. JAMA. 2010;303(18):1841-1847.
16. Mancia G, De Backer G, Dominiczak A, et al; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105-1187.
17. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-2572.
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
19. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):1-266.
20. Parazzini F, Menchini FF, Bortolotti A, et al. Frequency and determinants of erectile dysfunction in Italy. Eur Urol. 2000;37(1):43-49.
21. Aranda P, Ruilope LM, Calvo C, Luque M, Coca A, Gil de MA. Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish national study. Am J Hypertens. 2004;17(2):139-145.
22. Lemogne C, Ledru F, Bonierbale M, Consoli SM. Erectile dysfunction and depressive mood in men with coronary heart disease [published online ahead of print September 11, 2008]. Int J Cardiol.
23. Hodges LD, Kirby M, Solanki J, O'Donnell J, Brodie DA. The temporal relationship between erectile dysfunction and cardiovascular disease. Int J Clin Pract. 2007;61(12):2019-2025.
24. Vlachopoulos C, Aznaouridis K, Ioakeimidis N, et al. Arterial function and intima-media thickness in hypertensive patients with erectile dysfunction. J Hypertens. 2008;26(9):1829-1836.
25. Uslu N, Gorgulu S, Alper AT, et al. Erectile dysfunction as a generalized vascular dysfunction. J Am Soc Echocardiogr. 2006;19(3):341-346.
26. Lavie CJ, Messerli FH, Milani RV. Beta-blockers as first-line antihypertensive therapy the crumbling continues. J Am Coll Cardiol. 2009;54(13):1162-1164.
27. Bangalore S, Sawhney S, Messerli FH. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol. 2008;52(18):1482-1489.
28. Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366(9496):1545-1553.
29. Bakris GL, Fonseca V, Katholi RE, et al; GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292(18):2227-2236.
30. Kindermann M, Maack C, Schaller S, et al. Carvedilol but not metoprolol reduces beta-adrenergic responsiveness after complete elimination from plasma in vivo. Circulation. 2004;109(25):3182-3190.
31. Gabriel R, Alonso M, Segura A, et al; ERICE Cooperative Group. Prevalence, geographic distribution and geographic variability of major cardiovascular risk factors in Spain. Pooled analysis of data from population-based epidemiological studies: the ERICE Study. Rev Esp Cardiol. 2008;61(10):1030-1040.
32. Lloyd-Jones D, Adams RJ, Brown TM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46-e215.
33. Friedman O, McAlister FA, Yun L, Campbell NR, Tu K. Antihypertensive drug persistence and compliance among newly treated elderly hypertensives in Ontario. Am J Med. 2010;123(2):173-181.
34. Broeders MA, Doevendans PA, Bekkers BC, et al. Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production. Circulation. 2000;102(6):677-684.
35. Dessy C, Saliez J, Ghisdal P, et al. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation. 2005;112(8):1198-1205.
36. Cocco G. Erectile dysfunction after therapy with metoprolol: the Hawthorne effect. Cardiology. 2009;112(3):174-177.
37. Silvestri A, Galetta P, Cerquetani E, et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J. 2003;24(21):1928-1932.